"Challenges and Controversies in Alzheimer's Treatment: Navigating the Hype and Hope"
Two new drugs, lecanemab and donanemab, have emerged as potential "breakthrough" treatments for Alzheimer's disease by targeting the underlying cause of the disease, beta-amyloid plaques. However, their beneficial effects are minimal, with potential side effects and high costs. Experts debate the value of these treatments, with some emphasizing the importance of hope for patients and families, while others advocate for a focus on prevention, as lifestyle and environmental factors could delay or prevent dementia.